tbuckley/cabot-search huggingface dataset:
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen
Authors: Christy L. Osgood, Meredith K. Chuk, Marc R. Theoret, Lan Huang, Kun He, Leah Her, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research (2017)

Abstract On January 28, 2016, the FDA approved eribulin (Halaven; Eisai Inc.) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. The approval was based on results from a single, randomized, open-label, active-controlled trial (Trial E7389-G000-309) enrolling 452 patients with advanced, locally recurrent or metastatic liposarcoma or leiomyosarcoma. Patients were randomized to eribulin 1.4 mg/m2 intravenously (i.v.) on days 1 and 8 or dacarbazine 850, 1,000, or 1,200 mg/m2 i.v. on day 1 of a 21-day cycle. There was a significant improvement in overall survival [OS; HR, 0.75; 95% confidence interval (CI), 0.61–0.94; P = 0.0119, stratified log-rank] for the overall population. Estimated median OS was 13.5 months (95% CI, 11.1–16.5) in the eribulin arm and 11.3 months (95% CI, 9.5–12.6) in the dacarbazine arm (HR, 0.75; 95% CI, 0.61–0.94; P = 0.011).There were no differences in PFS for the overall population. The effects of eribulin were limited to patients with liposarcoma (n = 143) based on preplanned, exploratory subgroup analyses of OS (HR, 0.51; 95% CI, 0.35–0.75) and progression-free survival (PFS; 0.52; 95% CI, 0.35–0.78). Response rates in both treatment arms were less than 5% in the overall population and in the liposarcoma subgroup. The safety profile was similar to that previously reported for eribulin. The FDA determined that, based on the data reviewed, the benefit–risk assessment for eribulin is positive for patients with advanced, pretreated liposarcoma. Clin Cancer Res; 23(21); 6384–9. ©2017 AACR.
Project for a Scientific Psychiatry
Authors: Stephan Heckers
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract P5-13-03: Prospective study of work limitations in breast cancer patients (pts) undergoing curative chemotherapy (CTx)
Authors: AJ Tevaarwerk, KA Buhr, W Conkright, A Onitilo, E Robinson, R Hegeman, H Ahuja, RW Kwong, R Nanad, A Dennee, T Koehn, ME Burkard, KB Wisinski, DA Wiegmann, ME Sesto
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Extensive Coagulation Profile in Children with Sickle Cell Disease and Its Role in Cerebral Micro-Vasculopathy
Authors: Raffaella Colombatti, Emiliano De Bon, Antonella Bertomoro, Sandra Casonato, Agostino Steffan, Vania Munaretto, Giuseppe Basso, Sartori Maria Teresa, Laura Sainati
Journal: Blood (2012)
Non Hodgkin Lymphoma (NHL) Distribution and Clinical Characteristics in a Mexican Registry with High Frequency of T Cell NHL: A Descriptive Study on Behalf of Mexican Hematology Study Group (MHSG).
Authors: Gregorio Ignacio, Francisco Tripp, Petty Rodríguez, Mario Martínez, Concepción Martínez, Elsa Ávila, Severiano Baltazar, Alva Zaragoza, Silvia Rivas, Eduardo E. Reynoso
Journal: Blood (2007)
Contents, Vol. 59, 1993
Authors: Giovanni A. Fava, Barrie R. Cassileth, Douglas A. Drossman, Howard Berenbaum, E.H. Friedman, Paul M.G. Emmelkamp, Patricia van Oppen, Bernhard Strauss, Manuela Burgmeier-Lohse, Gereon Heuft, Wolfgang Senf, T. Platz, B. Junkert, W. Tress, H. Schepank, F. Anagnostopoulos, Gr. Vaslamatzis, M. Markidis, Kl. Katsouyanni, St. Vassilaros, C. Stefanis, Wolfgang Wöller, Johannes Kruse, Petra Winter, Elmar J. Mans, Luciano Alberti, James D.A. Parker, Graeme J. Taylor, Michael Bagby, Douglas E. Webb, Jr., Joen Fagan, George M. Simpson
Journal: Psychotherapy and Psychosomatics (1993)
Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 (RANTES)
Authors: Ryan A Wilcox, Wada A David, Andrew L. Feldman, Sherine F Elsawa, Deanna M Grote, Steven C Ziesmer, Anne J Novak, Mark R. Pittelkow, Thomas E. Witzig, Stephen M Ansell
Journal: Blood (2008)
Abstract ES5-1: Breast cancer risk assessments: Who is high risk?
Authors: J Nangia
Journal: Cancer Research (2017)

Abstract What is my risk for breast cancer? This is a common question physicians are asked, and with the changing guidelines for breast cancer screening it is very important to have a good understanding of what a woman's risk for breast cancer is. Breast cancer risk assessments can be done based on family history, risk factors and personal history of prior breast biopsies. During this educational session we will review different models used to determine breast cancer risk as well as other factors that can increase or reduce breast cancer risk. Citation Format: Nangia J. Breast cancer risk assessments: Who is high risk? [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr ES5-1.
Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.
Authors: Harris V.K. Naina, Martha Q. Lacy, Angela Dispenzieri, Shaji Kumar, Philip R. Greipp, Thomas E. Witzig, Morie A. Gertz, S. Vincent Rajkumar
Journal: Blood (2005)
Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus
Authors: Judith R Glynn, Hilary Bower, Sembia Johnson, Catherine F Houlihan, Carla Montesano, Janet T Scott, Malcolm G Semple, Mohammed S Bangura, Alie Joshua Kamara, Osman Kamara, Saidu H Mansaray, Daniel Sesay, Cecilia Turay, Steven Dicks, Raoul E Guetiya Wadoum, Vittorio Colizzi, Francesco Checchi, Dhan Samuel, Richard S Tedder
Journal: The Lancet Infectious Diseases (2017)

BackgroundThe frequency of asymptomatic infection with Ebola virus is unclear: previous estimates vary and there is no standard test. Asymptomatic infection with Ebola virus could contribute to population immunity, reducing spread. If people with asymptomatic infection are infectious it could explain re-emergences of Ebola virus disease (EVD) without known contact.MethodsWe validated a new oral fluid anti-glycoprotein IgG capture assay among survivors from Kerry Town Ebola Treatment Centre and controls from communities unaffected by EVD in Sierra Leone. We then assessed the seroprevalence of antibodies to Ebola virus in a cross-sectional study of household contacts of the survivors. All household members were interviewed. Two reactive tests were required for a positive result, with a third test to resolve any discrepancies.FindingsThe assay had a specificity of 100% (95% CI 98·9–100; 339 of 339 controls tested negative) and sensitivity of 95·9% (89·8–98·9; 93 of 97 PCR-confirmed survivors tested positive). Of household contacts not diagnosed with EVD, 47·6% (229 of 481) had high level exposure (direct contact with a corpse, body fluids, or a case with diarrhoea, vomiting, or bleeding). Among the contacts, 12·0% (95% CI 6·1–20·4; 11 of 92) with symptoms at the time other household members had EVD, and 2·6% (1·2–4·7; 10 of 388) with no symptoms tested positive. Among asymptomatic contacts, seropositivity was weakly correlated with exposure level.InterpretationThis new highly specific and sensitive assay showed asymptomatic infection with Ebola virus was uncommon despite high exposure. The low prevalence suggests asymptomatic infection contributes little to herd immunity in Ebola, and even if infectious, would account for few transmissions.FundingWellcome Trust ERAES Programme, Save the Children.
Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series
Authors: Chezi Ganzel, Ory Rouvio, Hila Magen, Osnat Jarchowsky, Irit Avivi, Katrin Herzog, Cohen Yossi, Tamar Tadmor, Netanel A Horowitz, Merav Leiba, Arnon Nagler, Yael Cohen, Shlomo Bulvik, Dina Ben Yehuda, Jacob M. Rowe, Moshe E. Gatt
Journal: Blood (2016)
Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Authors: Koji Sasaki, Hagop M. Kantarjian, Susan O'Brien, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William G. Wierda, Naval Daver, Alessandra Ferrajoli, Koichi Takahashi, Preetesh Jain, Mary Beth Rios, Sherry Pierce, Elias J. Jabbour, Jorge E. Cortes
Journal: Blood (2016)
Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.
Authors: Michael W. Deininger, Hagop M. Kantarjian, Park Byung, Andreas Hochhaus, Charles L. Sawyers, Michele Baccarani, Insa Gathmann, Charlene So, Brian J. Druker, Francois Guilhot
Journal: Blood (2005)
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Authors: Gary Middleton, Daniel H Palmer, William Greenhalf, Paula Ghaneh, Richard Jackson, Trevor Cox, Anthony Evans, Victoria E Shaw, Jonathan Wadsley, Juan W Valle, David Propper, Harpreet Wasan, Stephen Falk, David Cunningham, Fareeda Coxon, Paul Ross, Srinivasan Madhusudan, Nick Wadd, Pippa Corrie, Tamas Hickish, Eithne Costello, Fiona Campbell, Charlotte Rawcliffe, John P Neoptolemos
Journal: The Lancet Oncology (2017)
Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study
Authors: Neil P. Shah, Ronald Paquette, Martin C. Müller, Susanne Saussele, Valentin Garcìa-Gutiérrez, Antonio Jiménez-Velasco, Franck-Emmanuel Nicolini, Michael J. Mauro, Francois-Xavier Mahon, Delphine Rea, Patricia Martin-Regueira, Milayna Subar, Li Li, Jeffrey H. Lipton
Journal: Blood (2016)
Cysteine transporter SLC3A1 promotes breast cancer tumorigenesis
Authors: Yang Jiang, Yuan Cao, Yongbin Wang, Wei Li, Xinyi Liu, Yixuan Lv, Xiaoling Li, Jun Mi
Journal: Theranostics (2017)

Cysteine is an essential amino acid for infants, aged people as well as patients with metabolic disorders.Although the thiol group of cysteine side chain is active in oxidative reactions, the role of cysteine in cancer remains largely unknown.Here, we report that the expression level of the solute carrier family 3, member 1 (SLC3A1), the cysteine carrier, tightly correlated with clinical stages and patients' survival.Elevated SLC3A1 expression accelerated the cysteine uptake and the accumulation of reductive glutathione (GSH), leading to reduced reactive oxygen species (ROS).ROS increased the stability and activity of PP2Ac, resulting in decreased AKT activity.Hence, SLC3A1 activated the AKT signaling through inhibiting PP2A phosphatase activity.Consistently, overexpression of SLC3A1 enhanced tumorigenesis of breast cancer cells, whereas blocking SLC3A1 either with specific siRNA or SLC3A1 specific inhibitor sulfasalazine suppressed tumor growth and also abolished dietary NAC-promoted tumor growth.Collectively, our data demonstrate that SLC3A1 promotes cysteine uptake and determines cellular response to antioxidant N-acetylcysteine, suggesting SLC3A1 is a potential therapeutic target for breast cancer.
Distribution of pericellular matrix molecules in the temporomandibular joint and their chondroprotective effects against inflammation
Authors: Wern Cui Chu, Shipin Zhang, Timothy J Sng, Yu Jie Ong, Wen-Li Tan, Vivien Y Ang, Casper B Foldager, Wei Seong Toh
Journal: International Journal of Oral Science (2017)

The objectives of this study were to (1) determine the distribution and synthesis of pericellular matrix (PCM) molecules (collagen VI, collagen IV and laminin) in rat temporomandibular joint (TMJ) and (2) investigate the effects of PCM molecules on chondrocytes against inflammation in osteoarthritis. Four zones (fibrous, proliferating, mature and hypertrophic) of condylar cartilage and three bands (anterior, intermediate and posterior) of disc were analysed by immunohistochemistry for the presence of PCM molecules in rat TMJs. Isolated chondrocytes were pre-treated with PCM molecules before being subjected to interleukin (IL)-1β treatment to stimulate inflammation. The responses of the chondrocytes were analysed using gene expression, nitric oxide release and matrix metalloproteinase (MMP)-13 production measures. Histomorphometric analyses revealed that the highest areal deposition of collagen VI (67.4%), collagen IV (45.7%) and laminin (52.4%) was in the proliferating zone of TMJ condylar cartilage. No significant difference in the distribution of PCM molecules was noted among the three bands of the TMJ disc. All three PCM molecules were expressed intracellularly by chondrocytes cultured in the monolayer. Among the PCM molecules, pre-treatment with collagen VI enhanced cellular proliferation, ameliorated IL-1β-induced MMP-3, MMP-9, MMP-13 and inducible nitric oxide synthase gene expression, and attenuated the downregulation of cartilage matrix genes, including collagen I, aggrecan and cartilage oligomeric matrix protein (COMP). Concurrently, collagen VI pretreatment inhibited nitric oxide and MMP-13 production. Our study demonstrates for the first time the distribution and role of PCM molecules, particularly collagen VI, in the protection of chondrocytes against inflammation. A type of collagen found surrounding cells in jaw cartilage may help protect against inflammation associated with osteoarthritis. Cells called chondrocytes, which are responsible for maintaining healthy joint cartilage, are surrounded by a thin matrix layer known as the pericellular matrix (PCM). While interactions between chondrocytes and PCM molecules have been analyzed in knee joints, little is known about PCM molecules in the temporomandibular joint, where the upper jaw links to the skull. Wei Seong Toh at the National University of Singapore and co-workers investigated three PCM molecules (collagen VI, collagen IV and laminin) in rat jaws, and discovered that collagen VI is the most widely distributed across jaw cartilage. Pre-treating chondrocytes with collagen VI reduced nitric oxide levels and limited potentially damaging expression of some genes, thereby protecting the cells from inflammation. The discovery could inform osteoarthritis treatments.
Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)
Authors: E Hamilton, V Borges, R Murthy, C Anders, D Cameron, L Carey, V Müller, G Curigliano, K Gelmon, G Hortobagy, I Krop, S Loibl, X Pivort, M Pegram, D Slamon, S Hurvitz, M Tsai, E Winer
Journal: Cancer Research (2017)

Abstract Background: ONT-380 is a highly selective small molecule inhibitor of HER2 kinase with nanomolar potency. Unlike dual HER2/EGFR agents, it does not inhibit EGFR at clinically relevant concentrations, decreasing the potential for EGFR-related toxicities (severe skin rash and diarrhea). In preclinical studies, ONT-380 demonstrated synergistic activity with T, and was active in HER2+ models of brain metastases (mets). In a Phase 1b study, ONT-380 was combined with C and T in pts with HER2+ MBC previously treated with trastuzumab emtansine (T-DM1) and T. Objective responses were seen, including in pts with brain mets. The combination was well tolerated, with low rates of Gr 3 diarrhea at the recommended dose (300 mg PO BID, equivalent to the single agent MTD). Based on these data, ONT-380 is now being evaluated in a Phase 2 study in combination with C and T (HER2CLIMB). Trial Design: The primary study objective is to assess the effect of ONT-380 vs. placebo given with C + T on progression-free survival (PFS) based on independent central review. Additional objectives include ORR, duration of response, clinical benefit rate, and safety. The study population includes adult pts with progressive HER2+ locally advanced or MBC who have had prior treatment with a taxane, T, pertuzumab and T-DM1 but not C or lapatinib. Pts with brain mets,including untreated or progressive mets, may be enrolled. 180 pts will be enrolled in North America and Europe. Pts are receiving C (1000 mg/mg2 PO BID for 14 days of a 21-day cycle) and T (8 mg/kg IV loading dose; 6 mg/kg IV once every 21 days), and are being randomized in a 2:1 ratio to ONT-380 300 mg PO BID or placebo. Pts with isolated CNS progression may continue on study treatment after undergoing local CNS therapy. An independent Data Monitoring Committee is monitoring pt safety. Citation Format: Hamilton E, Borges V, Murthy R, Anders C, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagy G, Krop I, Loibl S, Pivort X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-02-09.
Virtual attendance at an international physical activity meeting using Twitter: how can data visualisation provide a presence?
Authors: Graham Mackenzie, Andrew D Murray, Christopher W Oliver
Journal: British Journal of Sports Medicine (2017)

Attendance at international sports and physical activity conferences is extremely useful for networking but can be expensive in terms of professional time, conference fees, accommodation and travel. The use of social media, especially Twitter,1 has increased in many global meetings. It is now possible to map, virtually attend, influence and interact with a meeting, remotely making savings in terms of time and travel, as well as opening up opportunities for sharing research and facilitating global networking. Data science has progressed rapidly to create complex forms of visualisation to help us understand interactions between humans. The speed and rate at which data are produced can be phenomenal. ‘Big Data’ is now an acknowledged specialist area of science. Processing, analysing and relaying data present challenges. The main goal of visualisation is to present data clearly by graphical means without distortion.2 Twitter hashtags and handles (eg, @BJSM_BMJ) are a useful way of grouping data, studying and ultimately building networks.3 

For example, the 6th ISPAH International Congress on Physical Activity and Public Health4 ran between 16 and 19 November 2016 in Thailand. For the @ISPAH2016 meeting, the …
Transfusion with Washed vs. Unwashed Packed Red Cells in Coronary Artery Bypass Graft (CABG) Surgery: Major Outcome Differences
Authors: Wenche Jy, Orlando Gomez-Marin, Tomas A Salerno, Anthony Panos, Donald Williams, Sherry Shariatmadar, Max E Johansen, Carlos Bidot, Lawrence L Horstman, Yeon-Soong Ahn
Journal: Blood (2014)
Deregulated Expression of a Novel Oncogene, Ahi-1, in Murine Hematopoietic Cells Confers a Proliferative Advantage In Vitro and Leukemogenic Activity In Vivo and Enhances the Effects of BCR-ABL.
Authors: Leon Zhou, Ashley Ringrose, Ann E.-J. Lin, Xiaoyan Jiang
Journal: Blood (2006)
Inhibitory and Proliferation-Inducing Effects of Valproic Acid on Leukemic Stem Cells from Different Acute Myeloid Leukemias.
Authors: Gesine Bug, Xiaomin Zheng, Claudia Schoch, Brigitte Ruster, Kerstin Schwarz, Manuela Kampfmann, Dieter Hoelzer, Oliver G. Ottmann, Reinhard Henschler, Martin Ruthardt
Journal: Blood (2005)
Direct Myeloma Cell Invasion as One of the Major Causes of Renal Impairment In Myeloma A Pathological Analysis of Renal Findings In 41 Autopsied Cases
Authors: Amane Tagashira, Junichiro Takano, Shotaro Hagiwara, Makoto Mochizuki, Hisako Endo, Risen Hirai, Akira Tanimura, Masataka Takeshita, Hirokazu Murakami, Akiyoshi Miwa
Journal: Blood (2010)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Authors: Lesley Seymour, Jan Bogaerts, Andrea Perrone, Robert Ford, Lawrence H Schwartz, Sumithra Mandrekar, Nancy U Lin, Saskia Litière, Janet Dancey, Alice Chen, F Stephen Hodi, Patrick Therasse, Otto S Hoekstra, Lalitha K Shankar, Jedd D Wolchok, Marcus Ballinger, Caroline Caramella, Elisabeth G E de Vries
Journal: The Lancet Oncology (2017)
“Disjointed” approach to rare diseases is still failing patients, warn MPs
Authors: Adrian O’Dowd
Journal: BMJ (2017)

Many patients in England with rare diseases are still not receiving the right treatment despite a UK wide strategy being launched to improve care more than three years ago, MPs and peers have said.

In England, some people with rare diseases are struggling to access treatment and information about their condition and do not feel involved in decisions about their care.

These claims were made in a report1 published on 28 February by the All Party Parliamentary Group on Rare, Genetic, and Undiagnosed Conditions. The group received evidence from more than 300 …
Pharmacodynamic Effects of Administration of Maytansine Conjugated Anti-CD22 Monoclonal Antibodies to Cynomolgus Monkeys
Authors: Franklin Fuh, Reina Fuji, Kirsten A Poon, Dongwei Li, Clarissa David, Quyen Nguyen, Kathy Howell, Joseph Beyer, Paul Fielder, William Manning, Karen Berry, Vanitha Ramakrishnan, Andrew G. Polson, Allen Ebens, Saileta Prabhu, Marna Williams
Journal: Blood (2008)
Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)
Authors: Justyna Bartoszko, Tony Panzarella, Caroline Jane McNamara, Anthea Lau, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen W.L. Yee, Mark D. Minden, Rebecca Devlin, Vikas Gupta
Journal: Blood (2016)
Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes
Authors: George Mulligan, David I Lichter, Alessandra Di Bacco, Stephen J Blakemore, Allison Berger, Erik Koenig, Hugues Bernard, William L. Trepicchio, Bin Li, Sagar Lonial, Paul G. Richardson, Kenneth C. Anderson, Pieter Sonneveld, Jesús F San Miguel, Dixie-Lee Esseltine, Matthew Schu
Journal: Blood (2011)